<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author><author><style face="normal" font="default" size="100%">Delasalle, K.B.</style></author><author><style face="normal" font="default" size="100%">Alexanian, R.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary plasma cell leukaemia</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Haematology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Plasma cell leukaemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1994</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1994</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028097420&amp;partnerID=40&amp;md5=cf119157d106f09dc54948b4ec281b9a</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">88</style></volume><pages><style face="normal" font="default" size="100%">754 - 759</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Among 750 previously untreated patients with multiple myeloma, 27 (4%) presented with plasma cell leukaemia. All but one patient had high tumour mass and, when compared with comparable patients without leukaemia, more frequent extraosseous involvement, thrombocytopenia, high serum lactate dehydrogenase and hypodiploid plasma cells. Most patients also had complex cytogenetic abnormalities. Treatment with standard melphalan-prednisone was ineffective, with a median survival of 2 months, but more intensive chemotherapy induced responses in approxirnately one-half of the patients, with a median survival of 20 months. Primary plasma cell leukaemia usually results from the proliferation and extramedullary expansion of immature plasma cells and requires prompt and intensive chemotherapy.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :125Export Date: 21 February 2017</style></notes></record></records></xml>